文献速递乳腺癌

NRG-BR002:寡转移性乳腺癌一线系统治疗联合转移灶消融的随机II/III期试验

NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2026-10-07

NRG-BR002是一项随机II/III期试验,评估在寡转移性乳腺癌一线系统治疗基础上加用转移灶消融是否改善无进展生存期(PFS)。共129例患者随机分配至单纯系统治疗或联合消融(93%为SBRT)。结论不支持常规使用转移灶消融。

要点

  • 一线系统治疗联合转移灶消融未改善寡转移性乳腺癌的PFS或OS。
  • 消融组与单纯系统治疗组中位PFS分别为19.5个月和23.0个月(HR 0.92)。
  • 消融不应在临床试验外常规使用,除非用于姑息治疗。

核心结论

  • 在寡转移性乳腺癌患者中,一线系统治疗联合转移灶消融未改善PFS或OS。

研究设计与样本

  • NRG-BR002是一项在美国和加拿大开展的随机II/III期试验,纳入≤4个转移灶、原发灶控制、一线系统治疗≤12个月且无进展、所有可见转移灶适合SBRT或手术切除的患者,1:1随机分配至单纯系统治疗或联合转移灶消融。
  • 2014年12月至2019年9月共入组129例,125例符合分析;中位年龄54岁,79%为HR阳性/HER2阴性,60%为单发转移,50%有骨转移,37%仅骨转移;93%的消融采用SBRT。

主要发现

  • 未发生5级毒性。
  • 探索性分析提示,在治疗前循环肿瘤细胞(CTC)低或无的患者中,消融可能改善PFS。

临床怎么用

  • 转移灶消融不应在临床试验外常规用于寡转移性乳腺癌的一线治疗,除非用于姑息目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastasis-directed therapy is increasingly used for oligometastatic breast cancer, despite its uncertain benefit during first-line systemic therapy. We evaluated whether metastasis-directed ablation improves progression-free survival (PFS) compared with first-line systemic therapy alone in patients with oligometastatic breast cancer. METHODS: NRG-BR002 is a randomized phase II/III trial across US/Canadian institutions. Participants had ≤4 metastases, controlled primary disease, ≤12 months of first-line systemic therapy without progression with all visible metastases amenable to stereotactic body radiation therapy (SBRT) or surgical resection and were randomly assigned 1:1 to systemic therapy alone (no ablation) or with metastasis-directed ablation (ablation). The primary end point was PFS, defined as time to progression or death. Secondary end points included overall survival (OS) and toxicity. Circulating tumor cells (CTCs) were evaluated as exploratory biomarkers. RESULTS: From December 2014 to September 2019, 129 patients were enrolled; 125 were eligible for analysis. Median age was 54 years; 79% had hormone receptor-positive, human epidermal growth factor receptor 2‑negative disease, 60% solitary metastasis, 50% bone involvement, and 37% bone only. Ablation was delivered via SBRT for 93%. With 72 PFS events and a median follow-up of 29.9 months, median PFS was 23.0 months (no ablation) versus 19.5 months (ablation; hazard ratio [HR], 0.92 [70% CI, 0.71 to 1.17; 95% CI, 0.57 to 1.47]; one-sided P = .36; stratified P = .42). Thus, the trial did not proceed to phase III. OS did not differ significantly between arms (HR, 1.07 [95% CI, 0.60 to 1.89]; one-sided P = .41; stratified P = .52). No grade 5 toxicities occurred. Exploratory analysis suggested improved PFS with ablation in patients with low or absent pretreatment CTCs. CONCLUSION: The addition of metastasis-directed ablation added to first-line systemic therapy did not improve PFS or OS in patients with oligometastatic breast cancer. Ablation should not be routinely used outside of clinical trials, except for palliation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chmura SJ, Winter KA, Woodward WA, et al. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. J Clin Oncol. 2026. PMID: 42842849. doi:10.1200/JCO-26-00201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。